The approval of the first small interfering RNA (siRNA) drug Patisiran by FDA in 2018 marks
a new era of RNA interference (RNAi) therapeutics. MicroRNAs (miRNA), an important post …

Discovered a little over two decades ago, small interfering RNAs (siRNAs) and microRNAs
(miRNAs) are noncoding RNAs with important roles in gene regulation. They have recently …

RNA interference (RNAi) provides researchers with a versatile means to modulate target
gene expression. The major forms of RNAi molecules, genome-derived microRNAs …

Ten years after Fire and Melo's Nobel Prize for discovery of gene silencing by double-
stranded RNA, a remarkable progress was achieved in RNA interference (RNAi). Changes …

Since the revolutionary discovery of RNA interference (RNAi), a remarkable progress has
been achieved in understanding and harnessing gene silencing mechanism; especially in …

Small interfering RNA (siRNA) enables efficient target gene silencing by employing a RNA
interference (RNAi) mechanism, which can compromise gene expression and regulate gene …

RNAi therapeutics have been growing. Patisiran and givosiran, two siRNA-based drugs,
were approved by the Food and Drug Administration in 2018 and 2019, respectively …

The miRNA mimic technology (miR-Mimic) is an innovative approach for gene silencing.
This approach is to generate nonnatural double-stranded miRNA-like RNA fragments. Such …

In the past few years, therapeutic microRNA (miRNA) and small interfering RNA (siRNA) are
some of the most important biopharmaceuticals that are in commercial space as future …

Simple Summary RNA-based drugs are an attractive approach for personalized treatment of
cancer and other diseases. This review focuses on two related classes of short non-coding …